Markers predicting clinical benefit in breast cancer from microtubule-targeting agents-Reference-Cited by-同舟云学术

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

Published:2007-12 Issue: Volume:18 Page:xii15-xii20
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Pusztai L.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/18/suppl_12/xii15/6672959/mdm534.pdf

Reference51 articles.

1. The Pat-21 breast cancer model derived from a patient with primary Taxol® resistance recapitulates the phenotype of its origin, has altered beta-tubulin expression and is sensitive to ixabepilone;Jordan;Proc Am Assoc Cancer Res,2006

2. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer;Henderson;J Clin Oncol,2003

3. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients;Bria;Cancer,2006

4. A systematic review of taxane-containing regimens for metastatic breast cancer;Ghersi;Brit J Cancer,2005

5. Targeting the microtubules in breast cancer beyond taxanes: the epothilones;Cortes;Oncologist,2007

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using maximum plasma concentration (Cmax) to personalize taxane treatment and reduce toxicity;Cancer Chemotherapy and Pharmacology;2024-05-11

2. Resistance to taxane chemotherapies in prostate cancer;Therapy Resistance in Prostate Cancer;2024

3. Systematic Analysis of Genetic and Pathway Determinants of Eribulin Sensitivity across 100 Human Cancer Cell Lines from the Cancer Cell Line Encyclopedia (CCLE);Cancers;2022-09-19

4. Breast cancer: Muscarinic receptors as new targets for tumor therapy;World Journal of Clinical Oncology;2021-06-24

5. Mechanisms of Taxane Resistance;Cancers;2020-11-10